Clinical trial
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma…
NCT00328861 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00328861 |
|---|---|
| Title | Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer |
| Official title | Phase II Study in Metastatic Melanoma or Kidney Cancer Using Autologous Natural Killer Cells Plus Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma, Metastatic Kidney Cancer |
| Intervention type | Biological, Drug |
| Interventions | Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine |
| Enrollment | 8 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Apr 1, 2009 |
| First posted | May 22, 2006 |
| Last update posted | Nov 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: